May 6th, 2026

The call presents a cautiously constructive picture: management beat Q1 expectations, highlighted multiple high-growth, AI-driven and idiosyncratic end-market opportunities (Semi Metrology, SciY, security detection, BEST superconductors), and is delivering cost savings above original targets while reconfirming full-year guidance. These positives are balanced against meaningful near-term organic revenue declines, China and academic funding weaknesses, margin and mix pressures, and EPS softening in Q1. On balance, the positive operational momentum (strong bookings, large multi-year orders, and expanded cost savings) and reconfirmed guidance slightly outweigh the current headwinds.

Company Guidance

Bruker reconfirmed its full‑year 2026 guidance: reported revenue $3.57B–$3.60B (reported growth 4%–5% vs FY25) with organic revenue growth of 1%–2%, acquisitions contributing ~1.5% and an estimated FX tailwind of ~1.5%; it expects organic non‑GAAP operating margin expansion of 300–350 bps (netting to a 250–300 bps improvement vs FY25’s 12.6% after an ~50 bp FX headwind) and non‑GAAP EPS of $2.10–$2.15 (15%–17% reported growth; an ~8% FX headwind implies CER EPS growth of 23%–25%). Management said Q2 should return to organic revenue growth (low‑ to mid‑single digits) with a meaningful sequential step‑up in non‑GAAP operating margin and EPS as tariff/FX laps ease, citing Q1 as a strong start (Q1 revenue $823.4M, +2.7% reported; organic –4.4%; M&A +2.6%; FX +4.5%; BSI organic bookings high‑single‑digits; BSI book‑to‑bill >1.0x) and Q1 non‑GAAP gross and operating margins of 50% and 10.2%, Q1 non‑GAAP EPS $0.31, while tracking roughly $140M of annualized cost savings (up from a $100–120M target).